WO2004035034A3 - Clofarabine and taxane chemotherapy combination - Google Patents

Clofarabine and taxane chemotherapy combination Download PDF

Info

Publication number
WO2004035034A3
WO2004035034A3 PCT/US2003/032516 US0332516W WO2004035034A3 WO 2004035034 A3 WO2004035034 A3 WO 2004035034A3 US 0332516 W US0332516 W US 0332516W WO 2004035034 A3 WO2004035034 A3 WO 2004035034A3
Authority
WO
WIPO (PCT)
Prior art keywords
clofarabine
chemotherapy combination
taxane chemotherapy
combination
taxane
Prior art date
Application number
PCT/US2003/032516
Other languages
French (fr)
Other versions
WO2004035034A2 (en
Inventor
Steven D Weitman
Katherine Stephenson
Sean T Wilson
Original Assignee
Ilex Products Inc
Steven D Weitman
Katherine Stephenson
Sean T Wilson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilex Products Inc, Steven D Weitman, Katherine Stephenson, Sean T Wilson filed Critical Ilex Products Inc
Priority to AU2003287081A priority Critical patent/AU2003287081A1/en
Publication of WO2004035034A2 publication Critical patent/WO2004035034A2/en
Publication of WO2004035034A3 publication Critical patent/WO2004035034A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention provides for the treatment of cancers by a combination of clofarabine and a taxane derivative.
PCT/US2003/032516 2002-10-16 2003-10-14 Clofarabine and taxane chemotherapy combination WO2004035034A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287081A AU2003287081A1 (en) 2002-10-16 2003-10-14 Clofarabine and taxane chemotherapy combination

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41893802P 2002-10-16 2002-10-16
US60/418,938 2002-10-16
US45951203P 2003-04-01 2003-04-01
US60/459,512 2003-04-01

Publications (2)

Publication Number Publication Date
WO2004035034A2 WO2004035034A2 (en) 2004-04-29
WO2004035034A3 true WO2004035034A3 (en) 2004-07-22

Family

ID=32110200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032516 WO2004035034A2 (en) 2002-10-16 2003-10-14 Clofarabine and taxane chemotherapy combination

Country Status (2)

Country Link
AU (1) AU2003287081A1 (en)
WO (1) WO2004035034A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1875936B (en) * 2006-07-18 2010-05-19 济南康泉医药科技有限公司 Anticancer sustained release agent containing clorfarabine and cytotoxic drug

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014352A1 (en) * 1989-05-23 1990-11-29 Southern Research Institute 2-halo-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine nucleoside derivatives
WO2002074232A2 (en) * 2001-03-21 2002-09-26 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
WO2002076484A2 (en) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Combination of a taxane and a cyclin-dependent kinase inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014352A1 (en) * 1989-05-23 1990-11-29 Southern Research Institute 2-halo-9-(2-deoxy-2-fluoro-b-d-arabinofuranosyl) adenine nucleoside derivatives
WO2002074232A2 (en) * 2001-03-21 2002-09-26 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
WO2002076484A2 (en) * 2001-03-23 2002-10-03 Aventis Pharma S.A. Combination of a taxane and a cyclin-dependent kinase inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
STEPHENSON KATHERINE ET AL: "Antitumor effect of combination treatment with clofarabine and taxotere in the PC-3 human prostate tumor xenograft-model.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 44, July 2003 (2003-07-01), 94th Annual Meeting of the American Association for Cancer Research;Washington, DC, USA; July 11-14, 2003, July 2003, pages 159, XP001180212, ISSN: 0197-016X *
WILLIAMS L ET AL: "SIGNAL TRANSDUCTION", IDRUGS, CURRENT DRUGS LTD, GB, vol. 5, no. 5, 6 April 2002 (2002-04-06), pages 412 - 415, XP001179314, ISSN: 1369-7056 *

Also Published As

Publication number Publication date
WO2004035034A2 (en) 2004-04-29
AU2003287081A1 (en) 2004-05-04
AU2003287081A8 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
LTPA2019511I1 (en) Rapamycin derivative for the treatment of lung cancer
MXPA03010134A (en) Substituted cyclohexane-1,4-diamine derivatives.
WO2004045464A3 (en) Medical devices
TW200738270A (en) Method of treating depression using a TNFα antibody
TW200732349A (en) Anti-OX40L antibodies and methods using same
AU2003247798A1 (en) Nozzles and components thereof and methods for making the same
IL175512A0 (en) Methods of preparing aripiprazole crystalline forms
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2003080582A3 (en) Fredericamycin derivatives
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
MY130718A (en) Antitumor compounds and methods
AU2003290592A1 (en) Antitumor benzoylsulfonamides
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
TW200510398A (en) Novel compounds
WO2005000204A3 (en) Pancreatic cancer treatment
WO2004105696A3 (en) Combination therapy for the treatment of neoplasms
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2004035034A3 (en) Clofarabine and taxane chemotherapy combination
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
MXPA05009428A (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions.
UA85187C2 (en) 2-aminobenzoyl derivatives
WO2004035033A3 (en) Clofarabine and camptothecin chemotherapy combination
AU2003264707A1 (en) Use of a chrysanthellum extract
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP